Hello warrior fam! 👋 Sorry I’ve been quiet for the last few months. The loss of fellow warriors in this group (and also in my community on Insta) has profoundly impacted me and lead to deep reflection about the unfairness and inequitable outcomes of cancer and mortality. I felt like any update I post would seem trivial and unhelpful during this difficult time for many of you. Although I REALLY didn’t want to, I ended up accepting some standard of care and integrating radiation into my latest intense protocol. The reason for this was financial stress, tumour growth for the first time in 2.5 years, and knowledge that my cancer cells have down-regulated Heat Shock Proteins (which in theory makes them more sensitive to radiation). I chose long-course, low dose radiation (25x1.8Gy) and integrated sensitisation strategies, such as daily HBOT, intermittent fasting and a few repurposed drugs prior. For recovery and minimising side effects I’ve been doing RLT, hydrogen therapy, CDS, while maintaining a high level of ketones as they have anti-inflammatory effects (especially β-OHB which reduces oxidative stress in healthy cells). Today was my final fraction. Initially I negotiated 15 due to fear of both the short and long term side effects, but as I’ve tolerated it so well I decided to have the full 25. I am very lucky to have been referred to a new radiation oncologist who has been open to personalising the treatment and genuinely curious about the potential of HBOT, fasting and the ketogenic diet. Radiation to the pelvis in women nearly always results in infertility and induces early menopause. General side effects also include proctitis, incontinence, rectal inflammation and pain, fibrosis, etc. I’m very shocked to report I am yet to experience any side effects, with the exception of the two days I decided not to fast, didn’t do HBOT, and drank coffee and ate a typical western breakfast. I had to know for sure that the adjunctive modalities I’ve implemented have been truly effective and not placebo, so this is why I experimented with what a “typical” patient (ignorant about the impact of GKI) would likely eat. On those two days (and two days after) I had extreme fatigue and a little irritation in the rectal mucosa. As a result of this, I did a 3 day consecutive fast to try to stop the progression of the side effects and lo and behold… they went away! Unfortunately, prolonged fasting wasn’t / isn’t possible as weight loss impacts the accuracy of the markings and measurements needed for precision radiation (and I certainly don’t want ionising gamma rays blasting non-tumorous rectal mucosa and causing a secondary cancer through oncogenesis of healthy epithelial cells).

Dear all, this new classroom is just in the planning stage, let's make it happen! The idea is to create a crowdsourced classroom where members share real-life progress stories, connect with other members, and find renewed hope. What’s a story of progress and success? Any win, big or small. Remission, or just moving forward. Let's start small; we've got some recent success stories. @Jeff Boldrick , @Whitney Khan , can we post yours in the classroom to kick things off? Also recalling @Odette Rocha , @Michelle Love and @Hengameh Bolouri had great stories, if I remember correctly. Can we add yours too? Others with great stories, please share! No, it's not bragging, it's giving hope to others. Moving forward, all admins can add member success stories from the community to the classroom (with permission). How does that sound?

Hi all, this is a great lecture by the highly intelligent and humble Dr Tomas Duraj - a research partner of Prof. Seyfried who kindly wrote the foreword for my book. Obviously Prof. Seyfried is the GOAT, but I find Dr Duraj’s presentations about metabolic therapy and in particular his explanation of OXPHOS and AMPK much easier to digest.

Merry christmas everyone! I'm just listening to the latest podcast with Dr Casey Peavler and Tomas Duraj and they mention adding in carnitine to aid with ketosis. Has anyone tried this or have any experience with carnitine? https://youtu.be/DnKKsXBIxOY?si=Ugdze4WngJFxMyPo

https://www.facebook.com/share/p/1CU1QfHe5u/ Johns Hopkins’ New Mebendazole Patent and Its Significance for Cancer Therapeutics A recent public news article has highlighted a development that deserves serious attention within oncology and drug-repurposing research: Johns Hopkins scientists have patented a new crystalline form of mebendazole—referred to as polymorph C—designed to enhance its anti-cancer properties. Background: Why Mebendazole Matters Mebendazole is a benzimidazole-class anthelmintic with a well-characterised safety profile accumulated over ~40 years of clinical use. Beyond its antiparasitic activity, numerous preclinical studies have demonstrated: Microtubule inhibition in cancer cells Disruption of glucose metabolism in malignant tissues Interference with multiple signalling pathways (Hh, Wnt/β-catenin, Bcl-2) Selective cytotoxicity to tumour cells at concentrations tolerated by normal cells Despite these properties, clinical adoption has been limited largely because the original molecule is off-patent, making large-scale commercial trials financially unviable. What Johns Hopkins Has Patented The new patent centers on: Polymorph C — a redesigned crystalline form This form appears to demonstrate: Improved oral absorption Higher plasma concentrations Prolonged systemic exposure Greater potency in killing cancer cells in vitro compared with existing polymorphs This is scientifically notable, because mebendazole traditionally suffers from: Poor gastrointestinal absorption High inter-individual variability Low bioavailability unless taken with high-fat meals A more bioavailable crystalline form directly addresses these limitations. Synergy Through Transporter Inhibition The Johns Hopkins team also referenced co-administration with elacridar, a potent inhibitor of: P-glycoprotein (P-gp) Breast Cancer Resistance Protein (BCRP) These efflux pumps are responsible for removing chemotherapeutic agents from cancer cells.